The FDA has put the PMTA framework — the system that decides which nicotine pouches can legally be sold in the US — up for review. In a September 28 announcement, the agency said it intends to evaluate changes to the premarket tobacco product application framework, "including through initiation of new rulemaking to replace the current framework."

That is bigger than a tune-up. The FDA named three drivers: its experience implementing the 2021 PMTA rule, the widespread growth of an illicit and unregulated market, and the pace of new product introductions. It also pointed to a federal lawsuit in the Northern District of Texas challenging the current framework. Until anything changes, the agency says it will keep processing PMTAs and issuing decisions under the existing "appropriate for the protection of public health" standard, and any rewrite will go through rulemaking with public input.

What it means for pouches

Every nicotine pouch on the US market needs FDA authorization through a PMTA. ZYN has cleared that bar for multiple SKUs; most other applicants have been denied or have waited years. Manufacturers have long complained the process is opaque — slow timelines, shifting expectations, and denial letters that don't fully explain themselves.

The transparency angle landed two days later, when FDA's acting chief of staff published an agency-wide Transparency Roadmap laying out completed FY26 milestones and FY27 priorities. The pouch-relevant parts are the commitment to disclosing more of the agency's decision reasoning — the FDA has already disclosed more than 200 complete response letters covering 2020–2024 applications — and to publishing more review metrics. One caution for readers: the roadmap's disclosure initiatives are written largely around drug and biologic applications, so how far they extend to tobacco PMTAs isn't spelled out yet.

What's next

The concrete change to watch is rulemaking. If the FDA replaces the PMTA framework, it changes how every current and future pouch brand gets authorized — including smaller brands waiting on decisions, and the many products currently sold in the gray zone. The agency hasn't given a timeline, and it explicitly committed to public comment before any change. For now, nothing in the review process itself has changed: submissions continue, and decisions continue, under the old rules.

SOURCES:

• FDA press announcement, "FDA intends to evaluate changes to the PMTA regulatory framework," Sept 28, 2026: https://www.fda.gov/news-events/press-announcements/fda-intends-evaluate-changes-pmta-regulatory-framework
• FDA Voices, "Transparency Makes Modern Regulatory Science Stronger — FDA's Transparency Roadmap," Oct 2, 2026: https://www.fda.gov/news-events/fda-voices/transparency-makes-modern-regulatory-science-stronger-fdas-transparency-roadmap
• Tobacco Reporter, "FDA Releases Transparency Roadmap," Oct 2, 2026: https://tobaccoreporter.com/2026/10/02/fda-releases-transparency-roadmap/
• Compare authorized pouch brands at PouchFinder: https://pouchfinder.com/brand/zyn?utm_source=pouchdaily&utm_medium=article&utm_campaign=fda-pmta-overhaul